In particular, patients with chronic myeloid leukemia (CML) often require lifelong therapy with ABL1 tyrosine kinase inhibitors (TKIs), partly due to a persistent population of TKI-resistant leukemic stem cells (LSCs). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.